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Hyaluronan and proteoglycan link protein 2 (Hapln2) is important for the binding
of chondroitin sulfate proteoglycans to hyaluronan. Hapln2 deficiency leads to the
abnormal expression of extracellular matrix (ECM) proteins and dysfunctional neuronal
conductivity, demonstrating the vital role of Hapln2 in these processes. Studies have
revealed that Hapln2 promotes the aggregation of α-synuclein, thereby contributing
to neurodegeneration in Parkinson’s disease (PD), and it was recently suggested to
be in intracellular neurofibrillary tangles (NFTs). Additionally, the expression levels of
Hapln2 showed lower in the anterior temporal lobes of individuals with schizophrenia
than those of healthy subjects. Together, these studies implicate the involvement of
Hapln2 in the pathological processes of neurological diseases. A better understanding of
the function of Hapln2 in the central nervous system (CNS) will provide new insights into
the molecular mechanisms of these diseases and help to establish promising therapeutic
strategies. Herein, we review the recent progress in defining the role of Hapln2 in brain
physiology and pathology.
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INTRODUCTION
Parkinson’s disease (PD), Alzheimer’s disease (AD) and schizophrenia are neurological diseases
characterized by the dysfunction of certain types of neurons (Hardy and Higgins, 1992; Korth, 2012;
Ghosh et al., 2016). However, the molecular mechanisms underlying the pathological processes
of these brain disorders remain elusive. Accumulating evidence suggests that the pathogenesis of
these diseases involve abnormal protein aggregates (Hardy and Higgins, 1992; Korth, 2012; Ghosh
et al., 2016). For example, in PD, the formation of Lewy bodies comprising α-synuclein aggregates
leads to the degeneration of dopaminergic neurons in the substantia nigra (SN; Ghosh et al., 2016;
Wang et al., 2016). The deposition of amyloid beta protein induces neuronal cell death in the
development of AD (Hardy and Higgins, 1992). Recently, schizophrenia has been linked with the
abnormal deposition of disrupted in schizophrenia 1 (DISC1) aggregates (Atkin and Kittler, 2012;
Korth, 2012). Moreover, all of these three diseases have been linked with the dysfunction of the
ubiquitin-proteasome pathway (UPP; Lam et al., 2000; Bousman et al., 2010; Shen et al., 2013),
which balances protein synthesis with degradation (Tsukamoto and Yokosawa, 2006). Substrates for
degradation within this pathway are specified by E3 ubiquitin ligases (Ardley and Robinson, 2005),
and we recently demonstrated that the E3 ubiquitin ligases Hrd1, Gp78 and Parkin colocalized with
hyaluronan and proteoglycan link protein 2 (Hapln2; Wang et al., 2016).
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Studies have shown that Hapln2, also known as brain-derived
link protein1 (Bral1), is vital for neuronal conductivity and
the formation of the extracellular matrix (ECM), and besides
its potential role in the UPP, it has been identified as a
contributor to the pathological processes in several neurological
disorders. For example, Martins-de-Souza et al. (2009) showed
that the expression levels of Hapln2 in the anterior temporal
lobe are lower in patients with schizophrenia than those of
the control subjects, and Minjarez et al. (2013) suggested that
Hapln2 was probably in the neurofibrillary tangles (NFTs) from
AD brain. Our studies recently revealed that Hapln2 expression
levels were dramatically increased in the SN of PD patients
and in the 6-hydroxydopamine-induced rat PD model (Liu
et al., 2015; Wang et al., 2016). This review article summarizes
recent progress focusing on the roles of Hapln2 in the central
nervous system (CNS) under physiological and pathological
conditions, highlighting the therapeutic potential of Hapln2 in
neurological diseases.
HAPLN2 IN CNS PHYSIOLOGY
Hapln2 Protein Structure
The structure and roles of Hapln2 in the CNS have been
studied since around the turn of this century, when an analysis
of the gene now known as HAPLN2 revealed seven exons
encoding a polypeptide with an estimated molecular mass of
38 kDa (Hirakawa et al., 2000). The Hapln2 protein comprises
three modules, namely, a proteoglycan tandem repeat 1 (PTR1)
domain, a PTR2 domain, and an immunoglobulin-like fold
(Hirakawa et al., 2000; Spicer et al., 2003). Western blotting
results from Hapln2-EGFP transfected cell lysates have shown
that an anti-Hapln2 antibody recognizes a band of around
55 kDa, which is in accordance with the predicted molecular
mass (Wang et al., 2016). However, a band for Hapln2 of
∼48 kDa is detected from SN tissue lysates of adult rats, revealing
an inconsistency between the lysates from transfected cells and
those from adult brain tissues (Wang et al., 2016). Given that
Hapln2 was a kind of link protein, we attributed this discrepancy
to hyaluronic acid modifications.
Hapln2 Expression
The hyaluronan and proteoglycan link family of proteins consists
of four members: Hapln1, Hapln2, Hapln3, and Hapln4 (Spicer
et al., 2003). An amino acid sequence alignment demonstrated
that these four proteins have similarities of ∼52%–62% (Spicer
et al., 2003), with a high level of conservation among vertebrate
species. Northern analyses and EST database searches revealed
that Hapln2 and Hapln4 are specifically expressed in the brain,
with the levels of Hapln2 significantly higher than that of Hapln4
(Spicer et al., 2003). These data indicate that the four-link
proteins may have different roles.
Northern blot analyses by Hirakawa et al. (2000) showed
that HAPLN2 mRNA is expressed at high levels in the human
hippocampus, medulla oblongata, putamen, SN, thalamus, and
spinal cord but at lower levels in the cerebellum, cerebral cortex,
frontal lobe, and nucleus accumbens. By in situ hybridization,
we detected high expression levels of Hapln2 mRNA in the
SN, olfactory bulb, red nucleus, cerebellum, brain stem, and
hippocampus but relatively weak signals in the cerebral cortex of
adult rat brain (Wang et al., 2016). The differential expression
of Hapln2 among the various brain regions suggests that the
protein has different roles in areas of high expression (SN and
hippocampus) than in areas of low expression (cerebral cortex).
The discrepancy between these studies regarding the expression
in the cerebellum may reflect species specificity and/or the
different experimental approaches used.
Hapln2 in ECM Formation and Neuronal
Conductivity
Lecticans such as brevican and aggrecan mainly bind to the
hyaluronans, which are the major components of the ECM
in the brain (Yamaguchi, 2000; Theocharis et al., 2010).
The proposed function of the link proteins is to stabilize
these binding interactions (Oohashi et al., 2002; Bekku et al.,
2003). Northern blot analyses revealed that the expression of
Hapln2 largely coincides with that of brevican, a brain-specific
lectican (Hirakawa et al., 2000). Previous studies have shown
that aggrecan aggregates are denser in the presence of link
protein (Mörgelin et al., 1988, 1992; Oohashi et al., 2002).
Moreover, immunohistochemical analyses showed that the levels
of ECM proteins, such as versican V2, brevican, hyaluronan,
and tenascin-R, are much lower in the brain of mice with
Hapln2 deficiency (Bekku et al., 2010). These findings not only
reveal the proximity of Hapln2 and lecticans in the brain but also
indicate the potential role of Hapln2 in stabilizing the binding
between brain lecticans and hyaluronan (Hirakawa et al., 2000;
Figure 1).
Northern blot analyses have shown that Hapln2 expression
in the mouse brain begins at 20 days after birth and increases
with age (Hirakawa et al., 2000). Immunohistochemical analyses
revealed that the patterns of Hapln2 and versican V2 expression
are similar in the late developmental stage of cerebellar
development and in the adult mouse brain (Oohashi et al., 2002).
Moreover, Hapln2 colocalizes with versican at myelinated retinal
ganglion cell axons (Oohashi et al., 2002). The Ranvier nodes
could be marked by the voltage-gated Na+ channels antibody
(Oohashi et al., 2002). Interestingly, Hapln2 preferentially
localizes with versican at nodes of Ranvier in adult mouse
brain, as observed by labeling with antibodies against Hapln2,
voltage-gated Na+ channels and the contactin-associated protein
(Rasband et al., 1999; Oohashi et al., 2002).
As Na+ channel clustering coincides with myelination (Bekku
et al., 2010), it was suggested that Hapln2 may also affect the
clustering of the Na+ channels. Of note, the clustering of Na+
and K+ channels is critical for saltatory conduction (Oohashi
et al., 2002; Bekku et al., 2010). Although immunohistochemical
analyses showed that Hapln2 deletion did not affect the clustering
of Na+ and K+ channels, flash visual evoked potentials had
a longer latency and smaller amplitude in recordings from
Hapln2 knockout mice compared with those from wild-type
mice (Bekku et al., 2010). Besides, consistent with the previous
results mentioned above, immunostaining analysis demonstrated
that there were no signals of ECM proteins including brevican,
neurocan and versican at the CNS nodes in adult mice with
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FIGURE 1 | Physiological functions of hyaluronan and proteoglycan link protein 2 (Hapln2) in the central nervous system (CNS).
Hapln2 deletion (Susuki et al., 2013), suggesting the essential
role of Hapln2 in the formation of nodal ECM. Additionally,
Susuki et al. (2013) showed that single disruption of ECM
or paranodal barriers or axonal cytoskeletal scaffolds (CS)
had mild effects on the development of nodes, which was
consistent with the previous results to some degree (Bekku
et al., 2010). However, disruption of the paranodal barriers
and ECM, or paranodal barriers and CS, or ECM and CS
resulted in juvenile lethality and the robust decrease of clustering
of Na+ channels (Susuki et al., 2013), which indicates the
complex and complementary roles of the three elements in the
formation of nodes. Early studies showed that clustering of nodal
proteins such as neurofascin-186 (NF186) was responsible for
action potential (AP) propagation (Salzer, 2003; Susuki et al.,
2013). Further experiments suggested that there was a specific
interaction between Hapln2 and NF186 using pull-down method
(Susuki et al., 2013), suggesting the important role of Hapln2 in
AP propagation. All of these data indicated the important roles
of Hapln2 in clustering of Na+ channel, nodes formation and
AP propagation. However, more studies should be performed
to clarify the details about the relationship between Hapln2 and
the paranodal barriers or the CS in these processes during
the development.
As mentioned above, Hapln2 deficiency decreased the
expression of ECM-associated proteins (Bekku et al., 2010).
Moreover, diffusion-weighted magnetic resonance imaging and
real-time iontophoretic assays showed an increase in the
diffusion signals from the ECM in white matter in animals
with Hapln2 depletion (Bekku et al., 2010). What was more,
Hapln2 was essential for nodal ECM formation and interacted
with nodal protein NF186 directly (Susuki et al., 2013).
Altogether, these results suggest that Hapln2 alters neuronal
conductivity by affecting the extracellular diffusion barriers at
the nodes of Ranvier rather than by directly impacting saltatory
conduction (Figure 1).
HAPLN2 IN CNS PATHOLOGY
Hapln2 in PD
PD is characterized by the formation of Lewy bodies and
selective loss of dopamine neurons in the SN (Liu et al.,
2015; Wang et al., 2016). Despite the identification of a
variety of risk factors including genetic elements, impairments
in mitochondrial function and inflammatory responses, the
pathogenesis of PD still remains unclear (Shao et al., 2013;
Cruces-Sande et al., 2017; Billingsley et al., 2018; Segura-Aguilar
and Huenchuguala, 2018). However, clinical analyses and animal
experiments implicate the involvement of Hapln2 in PD. In a
quantitative proteomics study, we demonstrated that the protein
levels of Hapln2 were increased with the highest fold among
all the upregulated proteins in the SN region of PD patients
compared with the control subjects (Liu et al., 2015). This
increase in the SN was confirmed both at the mRNA and protein
levels by quantitative PCR and Western blotting analyses in a rat
model of PD 2 weeks after 6-hydroxydopamine treatment as well
as 4 weeks postlesion (Wang et al., 2016).
Flow cytometry and immunostaining analyses showed
that the overexpression of Hapln2 increased the death of
MES23.5 and primary neuronal cells (Wang et al., 2016).
Confocal imaging of these cells demonstrated that the
overexpressed Hapln2 formed aggregates, which were found
to colocalize with E3 ubiquitin ligases Hrd1, Gp78, and Parkin
(Wang et al., 2016). It is known that E3 ubiquitin ligases
involve in specifying and catalyzing the transfer of substrates
in the UPP (Uchida and Kitagawa, 2016). Moreover, the
treatment of MES23.5 cells with the proteasome inhibitor
MG132 increased Hapln2 levels, indicating that the UPP
pathway regulates Hapln2 degradation (Wang et al., 2016).
Of note, previous research showed that UPP dysfunction
via proteasome inhibition resulted in the degeneration of
dopaminergic neurons in vitro and in vivo (Kikuchi et al., 2003;
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FIGURE 2 | Possible roles of Hapln2 in Parkinson’s disease (PD), Alzheimer’s disease (AD), and schizophrenia. An upregulation of Hapln2 is observed in the
substantia nigra (SN) of PD brain. The high expression levels of Hapln2 promote the aggregation of α-synuclein, which contributes to the degeneration of dopamine
neurons and the pathophysiology of PD. Hapln2 has also been suggested in neurofibrillary tangles (NFTs). There is evidence showing the vital role of extracellular
matrix (ECM) proteins during neurogenesis and neuronal conductivity, which become dysfunctional in schizophrenia. As Hapln2 helps maintain the ECM, it may also
play a role in schizophrenia. Hapln2 colocalizes with several E3 ligases of the ubiquitin-proteasome pathway (UPP). The influence of Hapln2 on the ECM and UPP
may contribute to PD, AD, and schizophrenia, neurological diseases in which ECM and UPP dysfunction have been observed.
Sun et al., 2006). These and the more recent results suggest that
the increase in Hapln2 as a result of UPP dysfunction contributes
to PD pathology.
Immunostaining analysis of MES23.5 cells overexpressing
Hapln2 also showed an accumulation of α-synuclein, aggregates
of which were found to colocalize with Hapln2 (Wang et al.,
2016). Thus, Hapln2 may be another component of Lewy
bodies in PD, which primarily comprise α-synuclein (Castro-
Sánchez et al., 2018). The accumulation of α-synuclein not only
promotes the death of dopaminergic neurons but also activates
glial cells (La Vitola et al., 2018; Martinez et al., 2018). Mice
overexpressing wild-type α-synuclein exhibit marked microglial
activation (Su et al., 2008). Pathological α-synuclein aggregates
activate astrocytes (Yu et al., 2018). Moreover, knockout of
Hapln2 significantly reduces the fraction of α-synuclein that is
insoluble in extracts from SN and cerebellum of 6-month-old
mouse brain (Wang et al., 2016). These findings suggest that
Hapln2 may contribute to neurodegeneration by regulating the
activation of glial cells in the brain (Figure 2).
Hapln2 in AD
A variety of environmental and genetic factors have also been
implicated in the pathology of AD (Chin-Chan et al., 2015;
Kikis, 2017; Kocahan and Dog˘an, 2017). However, due to the
complexity of this disease, the underlying molecular mechanism
remains largely unknown. Although a major hallmark of AD
is the accumulation of intracellular NFTs (Manczak et al.,
2018), their insolubility impedes the identification of their
integral components (Perry et al., 1991; Minjarez et al., 2013).
Nevertheless, Benito and colleagues used different solubilization
methods to identify lots of polypeptides, including Hapln2,
in total homogenates of AD brain tissue containing NFTs by
tandem mass spectrometry (Minjarez et al., 2013; Sugawara et al.,
2018). However, there was no direct evidence for a colocalization
of Hapln2 with tau, the main component of NFTs.
Notably, both AD and PD are age-associated
neurodegenerative diseases with characteristic protein aggregates
(Bridi and Hirth, 2018; Daniele et al., 2018; Theofilas et al., 2018).
As mentioned above, the overexpression of Hapln2 promotes the
aggregate formation and is involved with neuron death and the
UPP in the pathology of PD (Wang et al., 2016). As Hapln2 was
found to colocalize with some E3 ligases (Wang et al., 2016), it
may also contribute to AD pathology via disruptions of the UPP.
Postmortem tissue samples from the hippocampus, superior and
middle temporal gyri, parahippocampal gyri, and the inferior
parietal lobes of AD patients exhibit signs of reduced proteasome
activity compared with those from control subjects (Keller et al.,
2000). However, further animal experiments and clinical studies
are needed to determine whether Hapln2 is a major constituent
of the aggregates in these diseases.
Frontiers in Aging Neuroscience | www.frontiersin.org 4 March 2019 | Volume 11 | Article 60
Wang et al. Hapln2 and Brain Disorders
Although high levels of Hapln2 in the hippocampus were
measured by in situ hybridization (Wang et al., 2016), the
function of Hapln2 in this brain region remains unknown.
The hippocampus is involved in learning and memory
(Portero-Tresserra et al., 2018; Wang D. et al., 2018), the
dysfunction of which is a major symptom of AD (Axelrud
et al., 2018). Behavioral tests in a mouse model of AD
revealed a significant impairment in contextual conditioning and
performance in pattern separation tests after neurogenesis in the
hippocampus was inhibited (Hollands et al., 2017). Moreover,
the performance of AD transgenic mice in spatial learning
and memory tasks improved when hippocampal neurogenesis
was enhanced by deep brain magnetic stimulation (Zhen
et al., 2017). Of note, the fate determination of neural stem
cells is guided by ECM components, such as the heparan
sulfate proteoglycans glypican and perlecan (Yu et al., 2017).
Given the vital role of Hapln2 in maintaining the ECM
scaffold (Bekku et al., 2010), whether Hapln2 is involved in
AD pathology by regulating hippocampal neurogenesis needs
further investigation.
Hapln2 in Schizophrenia
Although the pathophysiology of schizophrenia has not
been fully defined, genetic factors, epigenetic elements, and
abnormal neurotransmission in the hippocampus are important
contributors (Kim et al., 2018; Sugawara et al., 2018; Wang H. Y.
et al., 2018). Previous studies of postmortem brain tissues from
patients with schizophrenia revealed the presence of insoluble
aggregates containing DISC1 (Atkin and Kittler, 2012; Korth,
2012). The overexpression of DISC in neuroblastoma cells
leads to the formation of aggresomal deposits (Korth, 2012),
which can invade cells and recruit other proteins that may
contribute to the impairment of neuronal cells (Atkin and
Kittler, 2012; Korth, 2012). Hapln2 represents another potential
contributor, as a shotgun proteomic analysis of postmortem
anterior temporal lobe tissues showed that Hapln2 protein levels
are lower in schizophrenia patients than in control subjects
(Martins-de-Souza et al., 2009). Additionally, a convergent
pathway analysis indicated that there is dysregulation of the UPP
in schizophrenia (Bousman et al., 2010). As mentioned above,
the UPP is vital for protein catabolism via the degradation of
particular substrate proteins (Tsukamoto and Yokosawa, 2006).
The colocalization of Hapln2 with E3 ligases revealed in our
previous work suggests a potential function of Hapln2 in the
UPP (Wang et al., 2016), which suggesting that Hapln2 may
also contribute to the pathophysiology of schizophrenia through
dysfunction of UPP.
Moreover, it has been reported that ECM plays important
roles in regulating neurogenesis, axonal outgrowth,
synaptogenesis and cell migration (Bandtlow and Zimmermann,
2000; Faissner et al., 2010; Gundelfinger et al., 2010). The
analysis of the schizophrenia risk genes showed that most of
the genes were involved in the regulation of neuronal migration
and cell adhesion (O’Dushlaine et al., 2011; Lips et al., 2012;
Aberg et al., 2013). Additionally, the disruption of conduction
velocity has been suggested in patients of schizophrenia (Thaker,
2008; Takahashi et al., 2011). The study of schizophrenia animal
models indicated the reduction of conduction velocity, indicating
the important role of nerve conduction in schizophrenia (Roy
et al., 2007; Tanaka et al., 2009; Takahashi et al., 2011). As one
of the important components of ECM, Hapln2 may be involved
in the pathogenesis of schizophrenia through regulating the
neuronal migration and velocity of nerve conduction. More
studies should focus on the molecular mechanism of Hapln2 in
the pathogenesis of schizophrenia using animal models and
clinical analysis.
CONCLUSIONS
As a brain specific-hyaluronan and proteoglycan link protein,
Hapln2 plays vital physiological roles in the formation and
maintenance of the ECM scaffold. Studies in knockout mice
have also revealed that Hapln2 influences neuronal conductivity.
Several studies have revealed the involvement of Hapln2 in the
pathogenesis of neurological diseases including PD, AD and
schizophrenia, which provided new insights into the underlying
molecular mechanisms of brain disorders (Figure 2).
Current research suggested that Hapln2 was involved in
the formation of α-synuclein aggregates in PD pathology and
study in AD suggested that Hapln2 might be the component
of NFTs aggregates (Minjarez et al., 2013; Wang et al., 2016).
It is noteworthy that, besides PD, AD and Schizophrenia,
dysfunction of UPP system has also been implicated in some
other neurological diseases including Huntington’s disease (HD)
and amyotrophic lateral sclerosis (ALS; Zhao et al., 2016; Desai
et al., 2018; Harding and Tong, 2018; Thibaudeau et al., 2018).
Thus, it is likely that Hapln2 may also be involved in the
pathological processes of these diseases through the UPP system.
However, further studies of animal and clinical experiments
are needed to clarify these mechanisms and the precise role
that Hapln2 plays in these neurological disorders in the future.
Nevertheless, the restriction of Hapln2 expression to the brain
suggests that it is an important contributor.
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